Molecular genetic aspects of solid tumors in childhood

Seminars in Pediatric Surgery

Volumn 10, Issue 3, 2001, Pages 106-118

  Davidoff, Andrew M ^a   Hill, D Ashley ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS; ARTICLE; CANCER GENETICS; CARCINOGENESIS; CELL DIFFERENTIATION; CHILD; CHILDHOOD CANCER; GENETIC COUNSELING; GENETIC SCREENING; HUMAN; MOLECULAR GENETICS; NEUROBLASTOMA; PRIORITY JOURNAL; RISK ASSESSMENT; SOLID TUMOR; TREATMENT PLANNING; TUMOR GROWTH;

EID: 0034906257     PISSN: 10558586     EISSN: None     Source Type: Journal    
DOI: 10.1053/spsu.2001.24700     Document Type: Article

References (126)

1. Biology and genetics of human neuroblastomas
2. EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma
3. The role of chimeric paired box transcription factors in the pathogenesis of pediatric rhabdomyosarcoma
4. Acute promyelocytic leukemia: From genetics to treatment
5. First-line, single-agent Herceptin (R) (trastuzumab) in metastatic breast cancer: A preliminary report
6. Epidermal growth factor receptor expression and gene amplification in high-grade non-brainstem gliomas of childhood
7. Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells
8. Abl protein- tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors
9. Genetic predisposition to cancer and familial cancer syndromes
10. Familial Cancer Syndromes: The role of caretakers and gatekeepers
11. Genetics and the biologic basis of sarcomas
12. Molecular biology of neuroblastoma
13. Genetics of Wilms tumor
14. Cancer incidence, survival, and mortality for children younger than age 15 years
15. Different karyotypic patterns in early and advanced stage neuroblastomas
16. Cellular DNA content as predictor of response to chemotherapy in infants with unresectable neuroblastoma
17. Genetic staging of unresectable or metastatic neuroblastoma in infants: A Pediatric Oncology Study Group
18. Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumor
19. Transposition and amplification on oncogene-related sequences in human neuroblastomas
20. Conditional expression of N-myc in human neuroblastoma cells increases expression of α-prothymosin and ornithine decarboxylase and accelerates progression into S-phase early after mitogenic stimulation of quiescent cells
21. M-myc can cooperate with ras to transform normal cell in culture
22. Targeted expression of MYCN causes neuroblastoma in transgenic mice
23. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage
24. Consistent N-myc copy number in simultaneous or consecutive neuroblastoma samples from sixty individual patients
25. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas
26. Chromosomal aberrations in human neuroblastomas
27. Dissociation of suppression of tumorigenicity and differentiation in vitro effected by transfer of single human chromosomes into human neuroblastoma cells
28. Loss of heterozygosity for the short arm of chromosome 1 in human neuroblastomas. Correlation with N-myc amplification
29. Human neuroblastomas and abnormalities of chromosome 1 and 17
30. Genetic heterogeneity of neuroblastoma studied by comparative genomic hybridization
31. Gain of chromosome arm 17q and adverse outcome in neuroblastoma
32. Deletion mapping of chromosomes 14q and 1p in human neuroblastoma
33. Neurotrophic factors and their receptors
34. The nerve growth factor 35 years later
35. Inverse relationship between Trk expression and N-myc amplification in human neuroblastoma
36. Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma
37. Expression and function of TRK-B and BDNF in human neuroblastomas
38. Coexpression of mRNA for the full-length neurotrophin receptor trk-C and trk-A in favorable neuroblastoma
39. Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN
40. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells
41. Clinical relevance of CD44 cell-surface expression and N-myc gene amplification in a multicentric analysis of 121 pediatric neuroblastomas
42. Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance
43. Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma
44. Common solid tumors of childhood
45. Chromosomal imbalance in the Aniridia-Wilms' tumor association: 11p interstitial deletion
46. Genetic events in the development of Wilms tumor
47. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus
48. The candidate Wilms' tumor gene is involved in genitourinary development
49. Positional cloning and characterization of a paired box- and homeobox-containing gene from the aniridia region
50. Germline mutations in the Wilms' tumor suppressor gene are associated with abnormal urogenital development in Denys-Drash syndrome
51. Fine structure analysis of the WT1 gene in sporadic Wilms tumor
52. Infrequent mutation of the WT1 gene in 77 Wilms tumors
53. Loss of heterozygosity mapping in Wilms tumor indicates the involvement of three distinct regions and a limited role for nondisjunction or mitotic recombination
54. Familial Wiedemann-Beckwith syndrome and a second Wilms tumor locus both map to 11p15
55. Loss of imprinting of IGF2 is linked to reduced expression and abnormal methylation of H19 in Wilms tumour
56. Chromosome 11p15.5 regional imprinting: Comparative analysis of KIP2 and H19 in human tissues and Wilms tumors
57. Loss heterozygosity for chromosomes 16q and 1p in Wilms' tumors predicts an adverse outcome
58. Anaplastic Wilms' tumor, a subtype displaying poor prognosis, harbours p53 gene mutations
59. High telomerase reverse transcriptase (hTERT) messenger RNA level correlates with tumor recurrence in patients with favorable histology Wilms' tumor
60. Incidence of childhood cancer: Experience of a decade in a population-based registry
61. Ewing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation
62. The Ewing's sarcoma EWS/FLI-1 fusion gene encodes a more potent transcriptional activator and is a more powerful transforming gene than FLI-1
63. A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG
64. A variant Ewing's sarcoma translocation (7;22) fuses the EWS gene to the ETS gene ETV1
65. Fusion of a forkhead domain gene to PAX3 in the solid tumor alveolar rhabdomyosarcoma
66. Fusion of PAX3 to a member of the forkhead family of transcription factors in human alveolar rhabdomyosarcoma
67. Fusion of PAX7 to FKHR by the variant t(1;13)(p36;q14) translocation in alveolar rhabdomyosarcoma
68. Fusion of the EWS and WT1 genes in the desmoplastic small round cell tumor
69. Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma
70. Fusion of the dominant negative transcription regulator CHOP with a novel gene FUS by translocation t(12;16) in malignant liposarcoma
71. Fusion of the EWS and CHOP genes in myxoid liposarcoma
72. Fusion of the EWS gene to CHN, a member of the steroid/thyroid receptor gene superfamily, in a human myxoid chondrosarcoma
73. EWS and ATF-1 gene fusion induced by t(12;22) translocation in malignant melanoma of soft parts
74. Identification of novel genes, SYT and SSX, involved in the t(X;18)(p11.2;q11.2) translocation found in human synovial sarcoma
75. Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors
76. TPM3-ALK and TPM4-ALK in inflammatory myofibroblastic tumors
77. ALK fusion genes in the pathogenesis of a nonhematopoietic malignancy - Inflammatory myofibroblastic tumor (IMT)
78. Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis
79. The ETV6-NTRK3 gene fusion encodes a chimeric protein tyrosine kinase that transforms NIH3T3 cells
80. Congenital mesoblastic nephroma t(12;15) is associated with ETV6-NTRK3 gene fusion: Cytogenetic and molecular relationship to congenital (infantile) fibrosarcoma
81. Various regions within the alpha-helical domain of the COL1A1 gene are fused to the second exon of the PDGFB gene in dermatofibrosarcomas and giant-cell fibroblastomas
82. Transforming activity of the chimeric sequence formed by the fusion of collagen gene COL1A1 and the platelet derived growth factor b-chain gene in dermatofibrosarcoma protuberans
83. The dermatofibrosarcoma protuberans-associated collagen type I alpha1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB
84. Human proto-oncogene c-kit: A new cell surface receptor tyrosine kinase for an unidentified ligand
85. Stem cell factor is encoded at the S1 locus of the mouse and is the ligand for the c-kit tyrosine kinase receptor
86. Preferential localization of c-kit product in tissue mast cells, basal cells of skin, epithelial cells of breast, small cell lung carcinoma and seminoma/dysgerminoma in human: Immunohistochemical study on formalin-fixed, paraffin-embedded tissues
87. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors
88. c-kit is expressed in soft tissue sarcoma of neuroectodermic origin and its ligand prevents apoptosis of neoplastic cells
89. The metastatic ability of Ewing's sarcoma cells is modulated by stem cell factor and by its receptor c-kit
90. KIT expression in angiosarcomas and fetal endothelial cells: Lack of mutations of exon 11 and exon 17 of c-kit
91. Activating c-kit gene mutations in human germ cell tumors
92. KIT ligand (mast cell growth factor) inhibits the growth of KIT expressing melanoma cells
93. The Li-Fraumeni syndrome
94. Retinoblastoma: The disease, gene and protein provide critical leads to understand cancer
95. Retinoblastoma
96. Constitutional mutations of the hSNF5/INI1 gene predispose to a variety of cancers
97. Familial posterior fossa brain tumors of infancy secondary to germline mutation of the hSNF5 gene
98. Consistent cytogenetic aberrations in hepatoblastoma: A common pathway of genetic alterations in embryonal liver and skeletal muscle malignancies?
99. Complete and incomplete forms of Beckwith-Wiedemann syndrome: Their oncogenic potential
100. Hepatoblastoma and familial polyposis
101. Abnormal structure and expression of p53 gene and human hepatocellular carcinoma
102. Mutational hotspot in the P53 gene in human hepatocellular carcinomas
103. Hepatoma in a child with neurofibromatosis
104. Association between hepatoblastoma and polyposis coli
105. Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients
106. Molecular diagnosis of familial adenomatous polyposis
107. Gastrointestinal polyposis syndromes and hereditary nonpolyposis colorectal cancer
108. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A
109. Prevalence of pheochromocytoma and hyperparathyroidism in multiple endocrine neoplasia type 2A: Results of long-term follow-up
110. Molecular basis of childhood cancer
111. Cloning of the der(17)t(X;17)(p11;q25) of alveolar soft part sarcoma identifies the ASPL-TFE3 gene fusion, a new molecular diagnostic marker
112. TFE3, a transcription factor homologous to microphthalmia, is a potential transcriptional activator of tyrosinase and TyrpI genes
113. Translocation involving chromosome 22 in Ewing's sarcoma. A cytogenetic study of four fresh tumors
114. Chromosome study of Ewing' s sarcoma (ES) cell lines. Consistency of a reciprocal translocation t(11;22)(q24;q12)
115. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours
116. A novel chimera gene between EWS and E1A-F, encoding the adenovirus E1A enhancer-binding protein, in extraosseous Ewing's sarcoma
117. A new member of the ETS family fused to EWS in Ewing tumors
118. An intra-abdominal small round cell neoplasm with features of primitive neuroectodermal and desmoplastic round cell tumor and a EWS/FLI-1 fusion transcript
119. Intraabdominal desmoplastic small round cell tumor with EWS/ERG fusion transcript
120. Identification of two alternative fusion genes, SYT-SSX1 and SYT-SSX2, in t(X;18)(p11.2;q11.2)-positive synovial sarcomas
121. Fusion of SYT to two genes, SSX1 and SSX2, encoding proteins with homology to the Kruppel-associated box in human synovial sarcoma
122. A new fusion gene TPM3-ALK in anaplastic large cell lymphoma created by a (1;2)(q25; p23) translocation
123. Complex variant translocation t(1;2) with TPM3-ALK fusion due to cryptic ALK gene rearrangement in anaplastic large-cell lymphoma
124. Further demonstration of the diversity of chromosomal changes involving 2p23 in ALK-positive lymphoma: 2 Cases expressing ALK kinase fused to CLTCL (clathrin chain polypeptide-like)
125. Fusion of ETV6 to neurotrophin-3 receptor TRKC in acute myeloid leukemia with t(12;15)(p13;q25)